<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00168753</url>
  </required_header>
  <id_info>
    <org_study_id>IST-US-064-04-AME</org_study_id>
    <secondary_id>CBT/IST 64</secondary_id>
    <nct_id>NCT00168753</nct_id>
  </id_info>
  <brief_title>Community Based Trial for AMEVIVE®</brief_title>
  <official_title>An Open-Label Community-Based Study to Determine the Safety and Efficacy of an Extended Course of Alefacept, Following a Standard 12-Week Course of Amevive®, With Commonly Used Clinical Assessment Tools</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of treating subjects with up to 12 additional doses of alefacept.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Male and female subjects at least 18 years of age with moderate to severe plaque psoriasis
      treated with 12 weeks of alefacept 15 mg IM and who have not achieved the desired response.

      Dosing Groups: Subjects will receive either 4, 8, or 12 doses of alefacept 15 mg IM weekly
      immediately (within 14 days) following a standard 12-dose course of AMEVIVE® 15 mg IM.
      Determination of number of doses will be based on physician qualitative assessment at weeks 4
      and 8.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of treating subjects with up to 12 additional doses of alefacept 15 mg IM following a standard 12-week course of AMEVIVE.</measure>
    <time_frame>16 weeks, 20 weeks or 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects who achieve moderate improvement, significant improvement or clear, as assessed by the PQA score, at any time during the study,</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative change in PQA score from screening visit to best PQA score at any time in the study,</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the total number of doses received with the best efficacy reached, as assessed by PQA score, at any time during the study,</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-treatment for subjects who achieve moderate improvement, significant improvement or clear, as assessed by the PQA score, at any time during the study,</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The cumulative change in SSA score from screening visit to best SSA score at any time in the study,</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of the total number of doses received with the best efficacy reached, as assessed by SSA score, at any time during the study, and</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of subject assessment of efficacy with physician assessment of efficacy as measured by the SSA score and PQA score respectively.</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Moderate to Severe Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alefacept</intervention_name>
    <description>IM</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Amevive</other_name>
    <other_name>ASP0485</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must give written informed consent.

          2. Must have had moderate, moderately severe or severe chronic plaque psoriasis as
             determined by the investigator prior to initial treatment (baseline) with AMEVIVE.

          3. Must be 18 years of age or older.

          4. Must have completed a standard 12-week course of AMEVIVE and have received at least 10
             doses.

          5. Response to current AMEVIVE therapy must be less than a desired response as determined
             by the physician, and subject and some residual psoriasis must be present.

        Exclusion Criteria:

          1. Female subjects who are not postmenopausal for at least 1 year, surgically sterile, or
             not willing to practice effective contraception during the study.

          2. Nursing mothers, pregnant women, and women planning to become pregnant

          3. Current enrollment in any investigational study in which the subject is receiving any
             type of drug, biologic, or non-drug therapy.

          4. Treatment with another investigational drug, or approved therapy for investigational
             use, within 3 months of investigational drug administration.

          5. Treatment with systemic retinoids, systemic steroids, methotrexate, cyclosporine,
             azathioprine, thioguanine, etanercept, efalizumab, infliximab, adalimumab or
             mycophenolate mofetil or other systemic immunosuppressant agents within 4 weeks of
             investigational drug administration.

          6. Treatment with Ultraviolet B (UVB) phototherapy or Psoralen + Ultraviolet A (PUVA),
             within 4 weeks of investigational drug administration.

          7. Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g.,
             pneumonia, septicemia) within the 3 months prior to the first dose of investigational
             drug.

          8. History of &gt;3 cutaneous squamous cell carcinomas or any systemic malignancy.

          9. Skin lesions suspicious for malignancy.

         10. Known HIV, viral hepatitis, or tuberculosis infection.

         11. History of severe allergic or anaphylactic reactions.

         12. ALT or AST greater than three times the upper limit of normal.

         13. Significantly abnormal hematology (hemoglobin, hematocrit, platelets, white blood
             cells), as determined by the investigator.

         14. CD4+ T lymphocyte count at screening visit less than 250 cells/mm3.

         15. Known hypersensitivity to AMEVIVE or any of its components.

         16. Subject's inability to comply with study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Gold</last_name>
    <role>Principal Investigator</role>
    <affiliation>GoldSkin Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Monheit Dermatology Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayshore Dermatology</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jayne Fortson</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bakersfield Dermatology &amp; Skin Cancer Medical Group</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Greenberg</name>
      <address>
        <city>San Ramon</city>
        <state>California</state>
        <zip>94582</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Front Dermatology</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin and Cancer Associates</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Scannon</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Derm, Vein &amp; Research Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearlridge Dermatology</name>
      <address>
        <city>Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calumet Dermatology Associates</name>
      <address>
        <city>Calumet City</city>
        <state>Illinois</state>
        <zip>60477</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Greenberg</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David J. Coynik</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melissa Knuckles</name>
      <address>
        <city>Corbin</city>
        <state>Kentucky</state>
        <zip>40701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Eisen</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woodson Clinical Studies Group, Inc.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashua Dermatology</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jerry Bagel</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catskill Dermatology</name>
      <address>
        <city>Monticello</city>
        <state>New York</state>
        <zip>12701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marina I Peredo</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <zip>11787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buffalo Medical Group</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <zip>14221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Health Associates Dermatology</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Brodell</name>
      <address>
        <city>Warren</city>
        <state>Ohio</state>
        <zip>44481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Center of Roseberg</name>
      <address>
        <city>Roseburg</city>
        <state>Oregon</state>
        <zip>97470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Assoc of Plymouth Meeting</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Skin Care</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark Wallis</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Miller</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Flax</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Center</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140573 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extended dosing</keyword>
  <keyword>alefacept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alefacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

